CR11370A - Inhibidores de quinasas simil polo - Google Patents

Inhibidores de quinasas simil polo

Info

Publication number
CR11370A
CR11370A CR11370A CR11370A CR11370A CR 11370 A CR11370 A CR 11370A CR 11370 A CR11370 A CR 11370A CR 11370 A CR11370 A CR 11370A CR 11370 A CR11370 A CR 11370A
Authority
CR
Costa Rica
Prior art keywords
simil
kinase inhibitors
compounds
polo kinase
methods
Prior art date
Application number
CR11370A
Other languages
English (en)
Inventor
X Cao Sheldon
Feher Victoria
Ichikawa Takashi
Jones Benjamin
W Kaldor Stephen
A Kiryanov Andre
Liu Yan
Mcbride Christopher
Reddy Natala Srinivasa
Nie Zhe
a stafford Jeffrey
Lam Betty
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11370(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CR11370A publication Critical patent/CR11370A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Se proveen los compuestos de la siguiente formula para usar con quinasas en donde las variables son como se definen en la presente. Tambien se proveen composiciones farmaceuticas, kits y articulos de fabricacion que comprenden tales compuestos; metodos e intermediarios de utilidad para preparar los compuestos; y metodos de uso de dichos compuestos.
CR11370A 2007-09-25 2010-04-14 Inhibidores de quinasas simil polo CR11370A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97512707P 2007-09-25 2007-09-25
US3730308P 2008-03-17 2008-03-17

Publications (1)

Publication Number Publication Date
CR11370A true CR11370A (es) 2010-07-16

Family

ID=40219644

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11370A CR11370A (es) 2007-09-25 2010-04-14 Inhibidores de quinasas simil polo

Country Status (26)

Country Link
US (4) US20110201818A1 (es)
EP (3) EP2564850B1 (es)
JP (2) JP5372939B2 (es)
KR (2) KR20140097440A (es)
CN (2) CN103122001A (es)
AR (1) AR071729A1 (es)
AU (1) AU2008304417B2 (es)
BR (1) BRPI0817315A2 (es)
CA (2) CA2699607A1 (es)
CL (1) CL2008002852A1 (es)
CO (1) CO6270231A2 (es)
CR (1) CR11370A (es)
DO (1) DOP2010000091A (es)
EA (1) EA019487B1 (es)
EC (1) ECSP10010129A (es)
ES (1) ES2488966T3 (es)
GE (1) GEP20125704B (es)
MA (1) MA31763B1 (es)
MX (2) MX2010003249A (es)
MY (1) MY152283A (es)
NZ (1) NZ584760A (es)
PE (1) PE20090710A1 (es)
TN (1) TN2010000131A1 (es)
TW (1) TWI436769B (es)
WO (2) WO2009042711A1 (es)
ZA (1) ZA201002543B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
CN103122001A (zh) 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
CA2756809A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepin compounds
US8481525B2 (en) 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same
KR20120096474A (ko) * 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
KR20120094920A (ko) 2009-09-25 2012-08-27 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
WO2011079114A1 (en) 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc. Pteridinones as inhibitors of polo - like kinase
EA023173B1 (ru) 2010-04-06 2016-04-29 Юниверсити Хелс Нетворк Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並－咪唑並－吡啶並－二氮呯化合物
KR101952981B1 (ko) * 2011-07-07 2019-02-27 구미아이 가가쿠 고교 가부시키가이샤 니트로벤젠 화합물의 제조방법
WO2013058344A1 (ja) * 2011-10-21 2013-04-25 武田薬品工業株式会社 Plk1阻害剤の効果を予測する方法
KR20160070106A (ko) * 2013-10-18 2016-06-17 유니버시티 헬스 네트워크 Plk-4 억제제의 염 및 결정체들
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
TWI844006B (zh) * 2016-05-05 2024-06-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
SG11202111003UA (en) 2019-04-24 2021-11-29 Univ Health Network Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
EP3911654A4 (en) * 2020-03-27 2022-05-11 Uppthera PLK1 SELECTIVE DEGRADATION-INDUCING COMPOUND
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
EP4289852A4 (en) 2021-02-08 2025-02-26 NovaOnco JS Therapeutics Co., Ltd. 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EA005287B1 (ru) 1999-09-15 2004-12-30 Уорнер-Ламберт Компани Птеридиноны в качестве ингибиторов киназ
ES2299434T3 (es) 1999-09-17 2008-06-01 ABBOTT GMBH & CO. KG Inhibidores de kinasa utilizados como agentes terapeuticos.
EP1427730B1 (de) 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
EP2029599A1 (en) 2006-05-19 2009-03-04 Astra Zeneca AB Dihydropteridine compounds as anti proliferative agents
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
CN102746175B (zh) * 2007-03-22 2014-01-15 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
US8461149B2 (en) 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
CN103122001A (zh) 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009153197A1 (en) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors

Also Published As

Publication number Publication date
EP2197442B1 (en) 2012-09-12
US20090281092A1 (en) 2009-11-12
CL2008002852A1 (es) 2009-03-27
WO2009042711A1 (en) 2009-04-02
US20110201818A1 (en) 2011-08-18
TW200927135A (en) 2009-07-01
MA31763B1 (fr) 2010-10-01
WO2009042806A1 (en) 2009-04-02
MX2010003249A (es) 2010-11-09
EP2564850B1 (en) 2014-08-13
CA2700295A1 (en) 2009-04-02
US8202990B2 (en) 2012-06-19
EA201070395A1 (ru) 2010-10-29
EA019487B1 (ru) 2014-04-30
WO2009042711A4 (en) 2009-06-04
CN103122001A (zh) 2013-05-29
TN2010000131A1 (en) 2011-09-26
US8026234B2 (en) 2011-09-27
MY152283A (en) 2014-09-15
JP2010540464A (ja) 2010-12-24
AR071729A1 (es) 2010-07-14
KR101444924B1 (ko) 2014-10-07
EP2205241B1 (en) 2014-05-21
US20110082111A1 (en) 2011-04-07
US20100222575A1 (en) 2010-09-02
CA2699607A1 (en) 2009-04-02
KR20100087292A (ko) 2010-08-04
CO6270231A2 (es) 2011-04-20
AU2008304417B2 (en) 2013-07-18
EP2205241A1 (en) 2010-07-14
EP2564850A1 (en) 2013-03-06
EP2197442A1 (en) 2010-06-23
HK1145144A1 (en) 2011-04-08
MX2010003244A (es) 2010-04-21
GEP20125704B (en) 2012-12-10
ZA201002543B (en) 2011-11-30
AU2008304417A1 (en) 2009-04-02
US8318727B2 (en) 2012-11-27
DOP2010000091A (es) 2010-07-31
CN101917995A (zh) 2010-12-15
BRPI0817315A2 (pt) 2015-03-17
ES2488966T3 (es) 2014-09-01
PE20090710A1 (es) 2009-07-15
ECSP10010129A (es) 2010-06-29
TWI436769B (zh) 2014-05-11
JP2010540463A (ja) 2010-12-24
JP5372939B2 (ja) 2013-12-18
KR20140097440A (ko) 2014-08-06
NZ584760A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
CR11370A (es) Inhibidores de quinasas simil polo
CR20110135A (es) INHIBIDORES DE cMET
CR11827A (es) Activadores de glucoquinasa
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY32077A (es) Inhibidores de quinasa tipo polo
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
CO6311105A2 (es) Derivados sinteticos de producto natural con propiedades anti-inflamatorias
ECSP099529A (es) Inhibidores de cinasa mapk/erk
ECSP10010434A (es) Inhibidores de hsp90
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
ECSP099315A (es) Inhibidores de cinasa
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
NI201100035A (es) Agentes antifúngicos.
CO6331464A2 (es) Inhibidores de cinasa
ECSP11010817A (es) Agentes antifúngicos
UA99739C2 (ru) Ингибиторы polo-подобных киназ
CO6321260A2 (es) Derivados aromaticos de oxima como inhibidores de hsp90